AWM
MBRX icon

Avondale Wealth Management’s Moleculin Biotech MBRX Stock Holding History

Avondale Wealth Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed -$4K – 116
2018
Q3 		$4K Buy
+1
New +$3.77K ﹤0.01% 96

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Avondale Wealth Management's MBRX Position: Q4 2018 in Review

Avondale Wealth Management sold out of Moleculin Biotech (MBRX) in Q4 2018, closing a stake of 1 share — an estimated $4K sold.

Avondale Wealth Management first reported a position in MBRX in Q3 2018 and held it in 1 quarter. The position peaked at $4K in Q3 2018. 20 funds tracked by Wall St. Rank hold MBRX as of Q4 2018.

  • Avondale Wealth Management reported no remaining Moleculin Biotech position as of Q4 2018 after selling out during the quarter.
  • Avondale Wealth Management sold 1 Moleculin Biotech share in Q4 2018, an estimated $4K.
  • Avondale Wealth Management first reported a position in Moleculin Biotech in Q3 2018 and held it in 1 quarter.
  • Avondale Wealth Management's Moleculin Biotech position peaked at $4K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2018.

Based on Avondale Wealth Management's 13F filing for Q4 2018, filed 23 Jan 2019.